NVCTHealthcare · BiotechnologyThe 6 Wall Street analysts covering Nuvectis Pharma, Inc. hold a median 12-month price target of $35 — +97.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 5 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Nuvectis Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (89): The shares have been drifting up relative to others.
Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NVCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +97.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $39 |
| 24 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 July 2026 | Roth Capital | Maintains | Buy | $20 → $33 |
| 6 July 2026 | Roth Capital | Maintains | Buy | — |
| 22 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | Maxim Group | Initiates | Buy | — |
| 17 Mar 2025 | Laidlaw & Co. | Initiates | Buy | — |
| 25 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 July 2022 | Ladenburg Thalmann | Initiates | Buy | — |
| 10 May 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2022 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NVCT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Nov 2026, Nuvectis Pharma, Inc. returned +213.3% against +9.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 2% of US stocks
Cheaper than 91% of US stocks
Higher than 31% of US stocks
Higher than 30% of US stocks
Higher than 7% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nuvectis Pharma, Inc. has a market value of $631.3M and an enterprise value of $608.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$27.8M.
Free cash flow in the twelve months to 30 June 2026: −$19.5M.
Trailing P/E: −13.3×; forward P/E: −18.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nuvectis Pharma, Inc. employs 16 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nuvectis Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Nuvectis Pharma, Inc.’s Q3 2026 earnings call. The excerpt provides no details from the call.
Why it matters — The transcript is a source for NVCT watchers, but the provided excerpt does not indicate what was discussed.
Nuvectis Pharma said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco. The agreement covers ex-China rights to ciprocopan (NXP100) and NXP200.
Why it matters — The licensing agreement and stated move into late-stage development are relevant to NVCT watchers tracking the company’s development strategy.
Nuvectis said licensing ex-China rights to NXP100 and NXP200 transformed it into a late-stage clinical development company. The company also reported that its lead candidate, ciprocopan (NXP100), was approved in China in July 2026 for certain previously untreated PNH patients.
Why it matters — The update highlights a shift in Nuvectis’ development stage and a China approval for its lead candidate.
Nuvectis Pharma announced it will host a conference call and webcast on November 4, 2026, at 8:00 a.m. ET, to discuss recent business progress and third-quarter financial results for the period ended September 30, 2026.
Why it matters — NVCT watchers can use the scheduled call for updates on the company’s recent progress and quarterly results.
Nuvectis reported Phase 1b data for single-agent NXP200 in 27 patients with recurrent or progressive gliomas. RANO 2.0 objective response rates were 40.0% in high-grade glioma, including three complete responses, and 42.9% in low-grade glioma, including one complete response.
Why it matters — The reported response rates and complete responses provide clinical data on NXP200 in patients with recurrent or progressive gliomas.
The 6 Wall Street analysts covering Nuvectis Pharma, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Nuvectis Pharma, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvectis Pharma, Inc. 54 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Nov 2026, Nuvectis Pharma, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +97.7% from the last close, and Ticker Nerd's factor model ranks Nuvectis Pharma, Inc. 54 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nuvectis Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
Nuvectis Pharma, Inc. returned +213.3% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Nuvectis Pharma, Inc.’s Q3 2026 earnings call. The excerpt provides no details from the call.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.
CEO Mr. Ron Bentsur M.B.A. · 16 employees · United States · https://www.nuvectis.com
